The presentation on CYDY web site has been updated
Post# of 155125
(Total Views: 486)
Posted On: 09/26/2019 8:21:35 AM
The presentation on CYDY web site has been updated (sept 25):
https://content.equisolve.net/_541733032e42f4...-Final.pdf
With respect to the one from August 26 (I believe) there are some changes (some small reflecting timing):
700 mg responder rate post 10 Weeks has gone up to 92% (from 88%)
Potential licensing or partnering now is 2H2019 (was 2019, still there)
IND-Protocol for NASH Phase 2 now is 2H2019
Publication of combination therapy trial now is 2H2019
Initiate first ever monotherapy Phase 3 pivotal trial with self injectable 2H2019
BLA submission: remaining 2/3 by Nov/Dec 2009
GvHD interim results 1Q2020 (added)
Triple-Negative Breast Cancer study interim results 1H2020 (added, before study initial read of data (CTC) was 4Q2019)
Maybe there are some other minor differences but the new information might shed some light on the upcoming meeting.
However I don't believe this is the main reason. After all the "open subjects" left after last conference I believe this one will bring some major news.
I hope this is not wishful thinking but I welcome the news of more information that will ease anxiety one way or another.
GLTA
https://content.equisolve.net/_541733032e42f4...-Final.pdf
With respect to the one from August 26 (I believe) there are some changes (some small reflecting timing):
700 mg responder rate post 10 Weeks has gone up to 92% (from 88%)
Potential licensing or partnering now is 2H2019 (was 2019, still there)
IND-Protocol for NASH Phase 2 now is 2H2019
Publication of combination therapy trial now is 2H2019
Initiate first ever monotherapy Phase 3 pivotal trial with self injectable 2H2019
BLA submission: remaining 2/3 by Nov/Dec 2009
GvHD interim results 1Q2020 (added)
Triple-Negative Breast Cancer study interim results 1H2020 (added, before study initial read of data (CTC) was 4Q2019)
Maybe there are some other minor differences but the new information might shed some light on the upcoming meeting.
However I don't believe this is the main reason. After all the "open subjects" left after last conference I believe this one will bring some major news.
I hope this is not wishful thinking but I welcome the news of more information that will ease anxiety one way or another.
GLTA
(4)
(0)